Traws Pharma defers Phase 2a flu study after negative MHRA review

Traws Pharma, Inc. announced the deferral of its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM). This decision follows a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). Despite the setback, the company maintains that TXM retains potential for emergency use in bird flu outbreaks and is actively advancing alternative influenza antiviral candidates. Traws Pharma remains committed to developing long-acting influenza antivirals, with a cash runway extending to Q1 2027, and is designing new candidates to address regulatory concerns while preserving efficacy.